Sensei Biotherapeutics (NASDAQ:SNSE) Coverage Initiated at BTIG Research

Equities research analysts at BTIG Research started coverage on shares of Sensei Biotherapeutics (NASDAQ:SNSE) in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. The firm set a “buy” rating and a $55.00 price target on the stock. BTIG Research’s target price indicates a potential upside of 382.03% from the company’s current price.

A number of other equities research analysts have also recently weighed in on SNSE. Zacks Research upgraded shares of Sensei Biotherapeutics to a “hold” rating in a report on Tuesday, April 21st. Leerink Partners initiated coverage on shares of Sensei Biotherapeutics in a report on Monday, April 20th. They issued an “outperform” rating and a $50.00 price objective on the stock. Loop Capital set a $50.00 price objective on shares of Sensei Biotherapeutics in a report on Thursday, May 28th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Sensei Biotherapeutics in a report on Thursday, June 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Friday, April 24th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $48.00.

Sensei Biotherapeutics Stock Performance

Shares of SNSE opened at $11.41 on Thursday. The stock has a market cap of $15.29 million, a PE ratio of -0.08 and a beta of -0.25. Sensei Biotherapeutics has a fifty-two week low of $5.60 and a fifty-two week high of $36.76. The firm’s 50-day simple moving average is $24.13 and its two-hundred day simple moving average is $18.88.

Sensei Biotherapeutics (NASDAQ:SNSE) last announced its quarterly earnings data on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($130.83).

Insider Buying and Selling

In other news, major shareholder James Peyer sold 25,000 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $20.02, for a total transaction of $500,500.00. Following the sale, the insider owned 130,142 shares in the company, valued at $2,605,442.84. This represents a 16.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Millennium Management Llc sold 8,151 shares of the stock in a transaction that occurred on Tuesday, April 7th. The shares were sold at an average price of $31.01, for a total transaction of $252,762.51. Following the sale, the insider owned 133,986 shares in the company, valued at approximately $4,154,905.86. The trade was a 5.73% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have bought 46,980 shares of company stock worth $1,341,669 and have sold 48,067 shares worth $1,204,939. Corporate insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On Sensei Biotherapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its holdings in Sensei Biotherapeutics by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock worth $123,000 after purchasing an additional 1,100 shares during the last quarter. Bank of America Corp DE boosted its holdings in Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after purchasing an additional 32,719 shares during the last quarter. Stempoint Capital LP purchased a new stake in Sensei Biotherapeutics in the first quarter worth approximately $4,188,000. Finally, Vivo Capital LLC purchased a new stake in Sensei Biotherapeutics in the first quarter worth approximately $22,758,000. Hedge funds and other institutional investors own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.